LumiraDx (LumiraDx) Asset Impairment Charge : $0.0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Asset Impairment Charge?

LumiraDx's Asset Impairment Charge for the three months ended in Jun. 2023 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 was $0.0 Mil.

LumiraDx Asset Impairment Charge Historical Data

The historical data trend for LumiraDx's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Asset Impairment Charge Chart

LumiraDx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Asset Impairment Charge

96.32

LumiraDx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Asset Impairment Charge	Get a 7-Day Free Trial								-	-	-	-	-

LumiraDx Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

LumiraDx Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of LumiraDx's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

LumiraDx (LumiraDx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDXF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108

Website

https://www.lumiradx.com

LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.